Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an update.
RemeGen Co., Ltd. announced the composition of its board of directors and their respective roles within the company. The board includes executive, non-executive, and independent non-executive directors, who serve on various committees such as Audit, Remuneration and Appraisal, Nomination, and Strategy. This announcement provides clarity on the governance structure, potentially affecting decision-making and strategic directions, which could influence stakeholder engagement and company operations.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company focuses on developing innovative medicines and therapies to address unmet medical needs.
YTD Price Performance: -9.17%
Average Trading Volume: 1,556,837
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$13.01B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.